BEVERLY, MA – November 25, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company received notification from the Food and Drug Administration (FDA) that a waiver has been granted eliminating the need to study Brilacidin, for the prevention of Severe Oral Mucositis in Head and Neck Cancer (HNC) patients receiving chemoradiation, in pediatric populations.
The granting of this waiver now enables the Company to develop Brilacidin in a more focused manner in adult patient populations where Oral Mucositis has the greatest impact.
In other news, the Company will provide shortly an update on continuing clinical development of Brilacidin for Inflammatory Bowel Disease, including the status of planned clinical work in Ulcerative Proctitis/Ulcerative Proctosigmoiditis.